2 completed, 2 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 2 |
| Phase 1 | 1 | Completed 1 |
Follow ATI 7505: new trials by email Literature Review of ATI 7505 trials Research Report on ATI 7505
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Different Doses of Naronapride vs. Placebo in Gastroparesis Naronapride, Placebo - Gastroparesis | Phase 2 | Completed | Dr. Falk Pharma GmbH | 328 | 2023-01-03 | 2026-10-07 |
| A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome Placebo, 20 mg ATI 7505, 40 mg ATI 7505 - Post Prandial Distress Syndrome | Phase 2 | Terminated | Procter and Gamble | 6 | 2008-02-01 | 2009-06-17 |
| Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation ATI-7505 - Chronic Constipation | Phase 2 | Terminated | Procter and Gamble | 214 | 2007-07-01 | 2009-06-17 |
| Effect of ATI-7505 on Gastrointestinal Transit in Healthy Volunteers ATI-7505, Placebo - Healthy | Phase 1 / Phase 2 | Completed | Mayo Clinic | 48 | 2005-01-01 | 2010-03-29 |
Diabetes Mellitus (1) · Gastroparesis (1)
Procter and Gamble (2) · Dr. Falk Pharma GmbH (1) · Mayo Clinic (1)
United States (4) · Canada (2) · Belgium (1) · United Kingdom (1)
Bruce C Yacyshyn, MD (1) · Michael Camilleri, MD (1) · Tom G Todaro, MD (1)
2023 (1)